Webmild: eCrCl, 51 to 80 mL/min. moderate: eCrCl, 31 to 50 mL/min. severe: eCrCl, ≤30 mL/min. end-stage renal disease (ESRD): eCrCl, <10 mL/min. 2. Overall, there is minimal information about the effects of renal disease on psychotropic therapy; our goal here is to summarize available data. We have created quick reference tables highlighting ... WebCymbalta is was initially approved August 4, 2004. It is approved for the following indications: Major ... This information is found in all versions of the package insert …
Reference ID: 2860327 - Food and Drug Administration
WebSep 6, 2024 · Cymbalta should be given without regard to meals.Initial TreatmentMajor Depressive Disorder -- Cymbalta should be administered at a total dose of 40 mg/day (given as 20 mg twice daily) to 60 mg/day (given either once daily or as 30 mg twice daily). ... Please review the latest applicable package insert for additional information and … WebDec 2, 2024 · What is Cymbalta? Cymbalta is a selective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI). Duloxetine affects chemicals in the brain that may be unbalanced in people with … focus bell
DailyMed - CYMBALTA- duloxetine hydrochloride capsule
WebDuloxetine, sold under the brand name Cymbalta among others, is a medication used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, neuropathic … WebAug 1, 2016 · Pregabalin (Lyrica), gabapentin (Neurontin), amitriptyline (except in older adults), or duloxetine (Cymbalta) should be used as first-line treatment for painful diabetic peripheral neuropathy. The ... WebJul 22, 2013 · Duloxetine (Cymbalta) is FDA approved for management of diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. 11 A desirable effect of duloxetine in the setting of chronic pain is thought to be improvement in depression. ... Ofirmev [package insert]. San Diego, CA: Cadence Pharmaceuticals, Inc; 2010. focus behavioral health johnstown pa